Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences for HR+/HER2- Metastatic Breast Cancer
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences for HR+/HER2- Metastatic Breast Cancer
09/03/24, 1:05 PM
Location
san diegoIndustry
biotechnology
Type
partnership
Avenzo Therapeutics has entered into a clinical study collaboration and supply agreement with Gilead Sciences to evaluate the safety and efficacy of AVZO-021, in combination with Gilead’s Trodelvy, as a potential treatment for patients with HR+/HER2- breast cancer. Gilead will provide Trodelvy to Avenzo, who will conduct and sponsor the combination study. Both companies will retain all development and commercial rights to their respective compounds.
Company Info
Location
9171 towne centre drive, suite 380
san diego, california, united states
Additional Info
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients. The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California.